<DOC>
	<DOCNO>NCT01288417</DOCNO>
	<brief_summary>The objective study evaluate effect boceprevir ( steady state ) pharmacokinetics single dose raltegravir . The effect boceprevir pharmacokinetics single dose raltegravir also evaluate ( compare historical control ) . Furthermore , safety profile combination study .</brief_summary>
	<brief_title>Pharmacokinetic Study HCV Protease Inhibitor Boceprevir HIV Integrase Inhibitor Raltegravir</brief_title>
	<detailed_description>A considerable percentage HIV infect patient also infect hepatitis C virus ( HCV ) . HIV/HCV co-infected patient likely simultaneously use treatment HIV infection well HCV treatment . Therefore , important know drug-drug interaction occur combine treatment . Raltegravir HIV integrase inhibitor approve FDA 2007 . Boceprevir potent HCV NS3 serine protease inhibitor currently Phase III clinical development . Combined use boceprevir raltegravir expect give major drug-drug interaction raltegravir CYP3A substrate thus affect strong inhibition CYP3A boceprevir . Raltegravir metabolize UGT boceprevir know influence UGT . However , recent data indicate raltegravir P-gp substrate boceprevir substrate moderate inhibitor P-gp vitro . Even drug interaction expect , may recommend collect sufficient evidence case many case un-expected drug-drug interaction observe past . The current study design evaluate effect steady state boceprevir pharmacokinetics single dose raltegravir safety profile use combination . Furthermore effect single dose raltegravir study pharmacokinetics steady state boceprevir comparison historical control .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>HIV Integrase Inhibitors</mesh_term>
	<criteria>Subject least 18 old 55 year screen . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior first dose Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . Subject able willing sign Informed Consent Form prior screen evaluation . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , haematology urinalysis test within 4 week prior Day 1 . Results biochemistry , haematology urinalysis test within laboratory 's reference range . If laboratory result within reference range , subject include condition Investigator judge deviation clinically relevant . This clearly record . Subject normal blood pressure pulse rate , accord Investigator 's judgement . Documented history sensitivity/idiosyncrasy medicinal product excipients . Positive HIV test . Positive hepatitis B C test . Pregnant female ( confirm HCG test perform less 4 week Day 1 ) breastfeed female . Female subject childbearing potential without adequate contraception , e.g . hysterectomy , bilateral tubal ligation , ( nonhormonal ) intrauterine device , total abstinence , double barrier method , two year postmenopausal . They must agree take precaution order prevent pregnancy throughout entire conduct trial . Therapy drug ( two week precede dose ) , except paracetamol . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , psychiatric disorder , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . History current abuse drug , alcohol solvent . Inability understand nature extent trial procedure require . Participation drug trial within 60 day prior first dose . Donation blood within 60 day prior first dose . Febrile illness within 3 day first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>HCV infection</keyword>
	<keyword>interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>raltegravir</keyword>
	<keyword>boceprevir</keyword>
</DOC>